Add to ORKGThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licens
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance ...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Lice...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
DUE TO COPYRIGHT RESTRICTIONS ONLY AVAILABLE FOR CONSULTATION AT ASTON UNIVERSITY LIBRARY AND INFORM...
Copyright © 2014 Ewelina Trela et al. This is an open access article distributed under the Creative ...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-C...
This is an open access article distributed under the Creative Commons Attribution License, which per...
Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic mye...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
Includes bibliographical references. 'NHS RandD HTA Programme' -Cover. Spine title: Imatinib for chr...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Ila Tamascar, Jeyanthi RamanarayananDepartment of Medical Oncology, Roswell Park Cancer Institute, E...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance ...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Lice...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
DUE TO COPYRIGHT RESTRICTIONS ONLY AVAILABLE FOR CONSULTATION AT ASTON UNIVERSITY LIBRARY AND INFORM...
Copyright © 2014 Ewelina Trela et al. This is an open access article distributed under the Creative ...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-C...
This is an open access article distributed under the Creative Commons Attribution License, which per...
Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic mye...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
Includes bibliographical references. 'NHS RandD HTA Programme' -Cover. Spine title: Imatinib for chr...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
Ila Tamascar, Jeyanthi RamanarayananDepartment of Medical Oncology, Roswell Park Cancer Institute, E...
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...
This is an open access article. Unrestricted non-commercial use is permitted provided the original w...
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance ...